Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, Mail Stop A1920, Austin, Texas, USA.
Small Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA.
AAPS PharmSciTech. 2018 Jul;19(5):1971-1984. doi: 10.1208/s12249-017-0861-7. Epub 2017 Sep 18.
The use of amorphous solid dispersions to improve the bioavailability of active ingredients from the BCS II and IV classifications continues to gain interest in the pharmaceutical industry. Over the last decade, methods for generating amorphous solid dispersions have been well established in commercially available products and in the literature. However, the amorphous solid dispersions manufactured by different technologies differ in many aspects, primarily chemical stability, physical stability, and performance, both in vitro and in vivo. This review analyzes the impact of manufacturing methods on those properties of amorphous solid dispersions. For example, the chemical stability of drugs and polymers can be influenced by differences in the level of thermal exposure during fusion-based and solvent-based processes. The physical stability of amorphous content varies according to the thermal history, particle morphology, and nucleation process of amorphous solid dispersions produced by different methods. The in vitro and in vivo performance of amorphous formulations are also affected by differences in particle morphology and in the molecular interactions caused by the manufacturing method. Additionally, we describe the mechanism of manufacturing methods and the thermodynamic theories that relate to amorphous formulations.
无定形固体分散体用于提高 BCS II 和 IV 类活性成分的生物利用度,这在制药行业中持续受到关注。在过去的十年中,生成无定形固体分散体的方法已经在商业上可获得的产品和文献中得到很好的确立。然而,不同技术制造的无定形固体分散体在许多方面存在差异,主要是化学稳定性、物理稳定性以及体外和体内的性能。本文分析了制造方法对无定形固体分散体这些性质的影响。例如,药物和聚合物的化学稳定性可能受到熔融法和溶剂法中热暴露水平差异的影响。无定形含量的物理稳定性根据无定形固体分散体的热历史、颗粒形态和成核过程的不同而变化,不同方法制得的无定形制剂的体外和体内性能也受到颗粒形态和制造方法引起的分子相互作用的差异的影响。此外,我们还描述了制造方法的机制以及与无定形制剂相关的热力学理论。